COBOL is in the headlines again, and this time it is because of artificial intelligence (AI) – sparking conversations with tools emerging that claim t.

Technological trends are often short-lived and have no lasting effect. New programming languages show up every year, promising faster builds and simpler syntax. Although many competitors have entered ...

Java ranked third in the Tiobe Index for January 2026 at 8.71%, holding steady behind Python and C and just ahead of C++. Tiobe named C# its Programming Language of the Year for 2025 after the largest ...

Learn how to use advanced techniques like short-circuiting, parallel execution, virtual threads, and stream gatherers to maximize Java stream performance. My recent Java Stream API tutorial introduced ...

Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...

TIOBE Programming Index News – November 2025: C# Closes In on Java Your email has been sent The November 2025 TIOBE Index brings another twist below Python’s familiar lead. C solidifies its position ...

Recursion Pharmaceuticals trades at a $2.65bn valuation despite slow clinical progress, high cash burn, and no late-stage assets. RXRX's AI-driven drug discovery model is ambitious, but pipeline value ...

Community driven content discussing all aspects of software development from DevOps to design patterns. All you need to do is open an online editor and code away! Which is exactly what we’re going to ...

– Company Eligible to Receive Up to $25 Million, Including an Upfront Equity Payment of $7.5 Million – – Extends Rallybio Cash Runway to Mid-2027 – The REV102 program originated from a joint venture ...

In a series of stories, AL.com will continue to explore big ideas for transforming Birmingham - ideas, programs and initiatives aimed at making the city stronger, more prosperous, better educated and ...

Recursion has stumbled through an early test of its tech-enabled approach to drug discovery, reporting a hit on its phase 2 primary endpoint of safety and tolerability but failing to wow on the ...